Sector: MedicalISTA Pharmaceuticals, Inc. (NASDAQ: ISTA)
Ranking History
Scan Date: | 11/17/2009 |
Sector: | Medical |
Funamental : | 38 |
Technical : | 18 |
Performance : | 268 |
Overall: | 68 |
Number of Stocks: | 307 |
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 38 |
Technical : | 35 |
Performance : | 241 |
Overall: | 67 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 83 |
Technical : | 247 |
Performance : | 289 |
Overall: | 256 |
Number of Stocks: | 306 |
Headlines
- ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Nov 09, 2009 07:30 AM | ISTA
- ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
Nov 03, 2009 04:01 PM | ISTA
- ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the American College of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Oct 21, 2009 04:01 PM | ISTA
- ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference
Oct 20, 2009 12:00 PM | ISTA
- ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
Oct 02, 2009 12:15 PM | ISTA
- Eye Drops Win Unanimous FDA Approval (Nasdaq: ISTA)
Sep 12, 2009 10:04 AM | ISTA
- ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
Sep 10, 2009 11:00 AM | ISTA
- ISTA Pharmaceuticals' Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
Sep 08, 2009 07:45 PM | ISTA
- ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
Sep 08, 2009 07:04 PM | ISTA
- Be Prepared For These Huge Biotech Catalysts In September
Aug 21, 2009 11:21 AM | ALTH, AUXL, ENDP, ISTA, SPPI, THRX
- ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
Aug 25, 2009 04:00 PM | ISTA
- ISTA Pharmaceuticals Reports Second Quarter 2009 Financial Results and Raises Full Year Revenue Guidance
Aug 05, 2009 04:01 PM | ISTA
- ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
Jul 29, 2009 11:29 AM | ISTA
- Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jun 26, 2009 10:28 AM | ISTA
- ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
Jun 08, 2009 04:01 PM | ISTA
- ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jun 01, 2009 01:14 PM | ISTA
- ISTA Pharmaceuticals' First Quarter 2009 Revenue Increases 32% to $20.4 Million
May 07, 2009 04:01 PM | ISTA
- ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
May 07, 2009 03:00 PM | ISTA
- ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
Apr 17, 2009 04:00 PM | ISTA
- ISTA Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Mar 10, 2009 11:47 AM | ISTA
- Form 4 ROE WAYNE I For: Aug 20 (10K)
Aug 26, 2009 03:44 PM
- Form 4 MITRO THOMAS A For: Jun 10 (10K)
Jun 10, 2009 05:59 PM
- Form 4 ISTA PHARMACEUTICALS For: Feb 27 Filed by: MITRO THOMAS A (10K)
Mar 02, 2009 10:32 AM
- Form 4 ANIDO VICENTE JR For: Feb 25 (10K)
Feb 27, 2009 11:22 AM
- Form 4 ANIDO VICENTE JR For: Feb 24 (10K)
Feb 26, 2009 02:06 PM
- Form 4 MCGINLEY KATHLEEN For: Feb 17 (10K)
Feb 19, 2009 12:41 PM
- Form 4 McNamara Timothy For: Feb 09 (10K)
Feb 19, 2009 12:40 PM
- Form 4 GARRETT MARVIN J For: Feb 03 (10K)
Feb 05, 2009 07:10 PM
- Form 4 MITRO THOMAS A For: Feb 03 (10K)
Feb 05, 2009 07:10 PM
- Form 4 McNamara Timothy For: Feb 03 (10K)
Feb 05, 2009 07:07 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ISTA
|
Compare to S&P
|
| YTD |
481.94 %
|
381.63 %
|
| 4 Weeks |
1.21 %
|
0.12 %
|
| 12 Weeks |
-28.01 %
|
-32.13 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 100.00 %
|
|
EPS Growth in Last Year: 100.00 %
|
|
Sales Growth in Last Quarter: 33.97 %
|
|
Sales Growth in Last Quarter: 47.64 %
|
|
